TB Alliance is at the forefront of developing innovative treatments for tuberculosis (TB) and is actively transforming the drug development process. The organization manages the largest pipeline of new TB drugs in history, focusing on creating faster, more effective, and less toxic treatment regimens. Their efforts include a six-month treatment for drug-resistant TB, which has garnered attention for its potential to significantly improve patient outcomes. TB Alliance is also exploring the use of novel compounds, such as telacebec, which has shown promise not only for TB but also for other neglected diseases like Buruli ulcer. This compound works by inhibiting the mycobacterial cytochrome bc1 complex, leading to the depletion of ATP in the bacteria, ultimately resulting in their death.

In addition to drug development, TB Alliance emphasizes the importance of global collaboration and funding to address the challenges posed by TB and other neglected diseases. The organization highlights the need for increased investment in research and development, as current funding levels fall short of what is necessary to combat the TB pandemic effectively. By leveraging their extensive pipeline and scientific expertise, TB Alliance aims to deliver impactful innovations that can reach those in need, thereby contributing to the global effort to eradicate TB and improve public health outcomes.

United States

We envision a world where no one dies of tuberculosis. However, this cannot be achieved without improved, faster-acting, and affordable tuberculosis drug regimens that are available to all who need them. These new cures can bring renewed health, hope, and prosperity to millions. 

Since our inception in 2000, TB Alliance has led the global search for and development of new TB regimens, catalyzing the field and convening cross-sector partnerships to forge the progress that is urgently needed for better TB treatments.

TB Alliance

Company Details